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Abstract
Background: Identification of predictive biomarkers is essential for the successful development of targeted therapy. Insulin-
like growth factor 1 receptor (IGF1R) has been examined as a potential therapeutic target for various cancers. However,
recent clinical trials showed that anti-IGF1R antibody and chemotherapy are not effective for treating lung cancer.
Methodology/Principal Findings: In order to define biomarkers for predicting successful IGF1R targeted therapy, we
evaluated the anti-proliferation effect of figitumumab (CP-751,871), a humanized anti-IGF1R antibody, against nine gastric
and eight hepatocellular cancer cell lines. Out of 17 cancer cell lines, figitumumab effectively inhibited the growth of three
cell lines (SNU719, HepG2, and SNU368), decreased p-AKT and p-STAT3 levels, and induced G 1 arrest in a dose-dependent
manner. Interestingly, these cells showed co-overexpression and altered mobility of the IGF1R and insulin receptor (IR).
Immunoprecipitaion (IP) assays and ELISA confirmed the presence of IGF1R/IR heterodimeric receptors in figitumumab-
sensitive cells. Treatment with figitumumab led to the dissociation of IGF1-dependent heterodimeric receptors and
inhibited tumor growth with decreased levels of heterodimeric receptors in a mouse xenograft model. We next found that
both IGF1R and IR were N-linked glyosylated in figitumumab-sensitive cells. In particular, mass spectrometry showed that
IGF1R had N-linked glycans at N913 in three figitumumab-sensitive cell lines. We observed that an absence of N-linked
glycosylation at N913 led to a lack of membranous localization of IGF1R and figitumumab insensitivity.
Conclusion and Significance: The data suggest that the level of N-linked glycosylated IGF1R/IR heterodimeric receptor is
highly associated with sensitivity to anti-IGF1R antibody in cancer cells.
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Introduction
With its secreted ligands, IGF1 and IGF2, Insulin-like growth
factor 1 receptor (IGF1R) is highly expressed in many human
cancer cells, including gastric (GC) and hepatocellular carcinoma
(HCC) [1–5]. As a result, a variety of strategies inhibiting the
IGF1R signaling pathway have been developed over the past two
decades [6]. Among these, an anticancer therapeutic strategy using
fully humanized antibodies has become an important research
focus [7], because it has great potential for becoming successful
anti-cancer therapeutics that could effectively inhibit cancer cell
proliferation with low toxicity and provide clinical benefits when
administered in combination with chemotherapy [8–14]. A fully
humanized anti-IGF1R monoclonal antibody (figitumumab) has
been tested in phase III clinical trials; however, no statistically
significant improvement was demonstrated by administering
figitumumab along with standard chemotherapy to patients with
advanced non-small cell lung cancer (NSCLC) [15].
Many studies have shown that the A isoform of insulin receptor
(IR) is abnormally overexpressed in various cancer types and
might promote tumor growth [16–19]. This IR shares a high
sequence homology with IGF1R, particularly within the intracel-
lular kinase domain [7,20]. IR pro-receptors can form heterodi-
meric receptors (HRs) with IGF1R pro-receptors post-translation-
ally, prior to cleavage to generate two extracellular alpha subunits
and two beta subunits that contain extracellular, transmembrane,
and tyrosine kinase domains [21]. Therefore, when cells co-express
IGF1R and IR, the pro-receptors can heterodimerize to create
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in various tumor cells and specimens as a result of both IGF1R
and IR overexpression [2,25,26]. Consequently, the relative
abundance of IRs affects IGF system activation through HRs,
which responds to both insulin and IGFs [27–29]. In cancer cells
with high levels of IGF1R/IR HRs, IGF1 and IGF2 activate
various downstream signaling pathways through heterodimeric
receptors rather than through homodimeric IGF1Rs [30].
A number of studies have tried to identify predictive biomarkers
with preclinical and clinical relevance [15,31,32]. Identification of
predictive biomarkers for monitoring the efficacy of IGF1R
targeted therapy for appropriate patients, however, is still needed.
In the present study, we demonstrated that figitumumab possesses
a high affinity for IGF1R/IR heterodimeric receptors as well as
IGF1 homodimer receptors and inhibits the IGF/IGF1R signaling
axis in gastric cancer and hepatocellular carcinoma cells. In
addition, our data showed that functional membrane-bound
IGF1R/IR heterodimeric receptors play a major role in IGF1
signaling [26,33] and therefore may serve as biomarkers for
predicting sensitivity to anti-IGF1R antibody.
Results
Anti-proliferative effect of figitumumab
As a first step, we assessed the anti-proliferative effect of
figitumumab, a monoclonal antibody that prevents ligands from
binding to IGF1R [12], on 17 cancer cell lines (Figure 1A). Some
cells considered to be sensitive to figitumumab, such as SNU719,
HepG2, and SNU368, showed a dose-dependent decrease of cell
viability; IC30 value of figitumumab (growth inhibitions of ,30%)
for each cell line were 0.063 mg/ml, 0.062 mg/ml, and 0.047 mg/
ml, respectively (Table 1).
Figitumumab disrupts IGF1R signaling mainly through
AKT and STAT3 pathways and induces G1 arrest
To examine the mechanism through which figitumumab
inhibits cell proliferation, we examined whether there were any
differences in downstream signaling between sensitive and resistant
cells in the presence of serum after long-term treatment with serial
doses of figitumumab (Figure 1B). In this experiment, only
figitumumab-sensitive cells exhibited markedly decreased levels
of p-AKT and p-STAT3 in a dose-dependent manner; however,
there were no changes in the levels of p-ERK. We also observed
that figitumumab decreased the level of total cellular IGF1R in
SNU719 cells, suggesting that down-regulation of this receptor
might represent an antibody-mediated degradation process [8].
We investigated whether figitumumab induced down-regulation of
IR expression as well as IGF1R levels in other cells at several
different time points. Interestingly, figitumumab caused the rapid
decrease of total IGF1R levels after 3 hour in SNU668 and
SNU739 cells (IR-negative cells) but did not significantly down-
regulate either IR or IGF1R expression in the other cell lines
(Figure S1). In contrast, figitumumab did not down-regulate
pAKT, pERK, or pSTAT3 in resistant cells.
To determine IGF1R signal dependency in sensitive cells, we
next performed experiments with siRNA to silence IGF1R
expression (Figure S2A). The results indicated that IGF1R
sequence-specific siRNAs induced profound IGF1R down-regula-
tion without influencing IR expression and showed a clear
correlation between the ability of siRNA and figitumumab to
inhibit the phosphorylation of specific down-stream signals, such
as p-AKT and p-STAT3, only in sensitive cells. We also
investigated the effects of IGF1R knockdown on the proliferation
of sensitive cells and confirmed that silencing IGF1R expression
resulted in an anti-proliferative effect on sensitive cells (Figure
S2B). In short, these results showed that the anti-proliferative
effects of figitumumab are specifically mediated through the down-
regulation of AKT and STAT3 signaling pathways rather than
through the ERK signaling pathway in sensitive cells which have a
strong IGF1R signaling dependency.
To further analyze the mechanisms through which figitumumab
inhibited the proliferation and survival of cancer cells, we
conducted a flow cytometric analysis (Figure 1C). Figitumumab
induced a similar dose-dependent increase in the percentage
SNU719, HepG2, and SNU368 cell in the G1 Phase. However,
there was no increased rate of apoptosis (percent of sub-G1 cells;
data not shown). This analysis showed that figitumumab decreased
cell viability through cell cycle inhibition without inducing
apoptosis.
Antitumor activity of figitumumab in a xenograft tumor
model
We next sought further evidence of figitumumab activity in vivo
by using HepG2 to establish xenografts due to their sensitivity to
figitumumab in vitro. To assess the effect of figitumumab on tumor
growth in vivo, xenograft tumors were grown in athymic nude mice.
As shown as shown in Figure 1D, repeated weekly administration
of single dose of figitumumab (6.3 mg/kg body weight) to animals
bearing HepG2 tumors resulted in substantial tumor growth
inhibition for 21 d of figitumumab dosing and significantly
inhibited tumor growth at day 17 (P,0.01). In addition, we
tested the effect of figitumumab on IGF1R-related molecules after
1 d of figitumumab treatment. Figitumumab effectively reduced
the levels of phosphorylated IGF1R and IRS1 (Figure S3A).
Taken together, these data showed that treatment with a single
dose of figitumumab effectively inhibited the growth of tumors by
inhibiting IGF1R and IRS1 activation.
Overexpressed IGF1R and IR form IGF1R/IR heterodimeric
receptors in figitumumab-sensitive cells
To identify a target for predicting sensitivity to figitumumab,
expression of IGF1R related-proteins and downstream signaling
molecules were analyzed in parallel by Western blotting. Interest-
ingly, we found that figitumumab-sensitive cancer cells all
overexpressed IGF1R; basal expression levels of IR were also much
higher compared to that in other resistant cells (Figure 2A). Based
on a recent report [31], we expected that figitumumab would
specifically inhibit the growth of cells overexpressing IGF1R or its
phosphorylated form, but not ones overexpressing IR because
figitumumab does not bind to IRs [12]. However, IR protein levels
were more responsive to figitumumab than any other protein. As
shown in Figure 1A, the anti-proliferative effect of figitumumab was
weaker in cells overexpressing only IGF1R, such as SNU668 and
SNU739, than in cells overexpressing both IGF1R and IR. This
finding suggested that different in vitro sensitivities of cells to
figitumumab is associated with both IGF1R and IR levels which in
turn can affect the level of IGF1R/IR heterodimeric receptors [2].
Since it is commonly known that IGF1R and IR can form
heterodimers when both are co-overexpressed due to their highly
homologous structures [2], we performed immunoprecipitation
experiments to determine whether IGF1R interacts with IR to form
heterodimer in figitumumab-sensitive cells. As shown in Figure 2B,
cells overexpressing both IGF1R and IR, such as SNU719, HepG2,
and SNU368, contained IGF1R/IR heterodimers. The SNU601
cell line, which showed modest sensitivity to figitumumab, also
contained IGF1R/IR heterodimers. To determine whether figitu-
mumab preferentially recognizes IGF1R/IR heterodimeric recep-
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experiments using figitumumab as the antibody used for immuno-
precipitation. Significant levels of both IGF1R and IR in
figitumumab-sensitive cells were detected in figitumumab immu-
noprecipitates, suggesting that this antibody has a superior ability to
recognize both the IGF1R homodimer and IGF1R/IR heterodi-
mer predominantly in sensitive cells (Figure S4).
We also quantitatively measured IGF1R, IR, and IGF1R/IR
HR levels using specific ELISAs with antibodies that specifically
recognize IGF1R or IR and do not cross-react with each other. We
compared 11 cancer cell lines, including MCF7 (Figure S5) which
has been evaluated in a previous study [2]. The levels of IR ranged
from 0.08 to 2.3 ng/50 mg total cellular proteins, and IGF1R levels
ranged from 0.50 to 10.6 ng/50 mg total cellular proteins (Table 2).
These results indicated that the expression of IGF1R and IR were
similar, and most ELISA results correlated closely with the Western
blotting results (Figure 2A). The cellular level of IGF1R/IR HRs
ranged from 0.39 to 0.99 ng/50 mg total cellular proteins. The level
of HRs was higher in sensitive cells than resistant cells (Figure 2C),
suggesting that the expression level of the IGF1R/IR heterodimeric
receptor significantly correlated with drug sensitivity.
Formation of IGF1 ligand-dependent IGF1R/IR
heterodimer is inhibited by anti-IGF1R antibody
To further define the mechanism of anti-proliferative figitumu-
mab activity related to IGF1R/IR heterodimer expression, we also
examined changes in ligand-dependent heterodimeric receptor
expression (Figure 2D). We found that the heterodimers bound to
IGF1 ligands, but this IGF1 ligand-dependent formation was
suppressed by figitumumab in sensitive cells. In SNU368, it
appeared that figitumumab suppressed not only IGF1 ligands
bindingtotheHRs,butalsotheexpressionofIGF1R/IRHRsinthe
absence of IGF1 ligand. Heterodimeric receptor levels in SNU638
and SNU354 cells, however, were relatively stable in the presence of
figitumumab. Additionally, there was no detectable insulin-depen-
dent heterodimer formation or dissociation due to figitumumab.
Phosphorylation in response to 100 nM insulin was also not reduced
by figitumumab (Figure S6). Taken together, the results from this
experiment demonstrated that IGF1R/IR heterodimers responded
well to IGF1, and blocking of IGF1 by figitumumab induced the
down-regulation of IGF1 ligand-dependent IGF1R/IR heterodimer
formation in the drug-sensitive cell lines.
Selective overexpression of IR induces heterodimeric
receptor formation and enhances the anti-proliferative
effect of figitumumab
To evaluate whether the effect of figitumumab was restricted to
SNU719, HepG2, or SNU368 cells, we performed studies in cells
with low expression levels of IR, including SNU739 and SNU886
cells, transfected with pcDNA3.1-IR which induced high expres-
sion of IR. As shown in Figure 3A, IR expression levels in the
transfected cells increased remarkably compared to cells trans-
fected with the pcDNA3.1(-) empty vector. Moreover, IGF1R/IR
Table 1. Anti-proliferative effect of figitumumab in gastric cancer and hepatocellular carcinoma cells.
GC cells Figitumumab IC
30 (mg/mL) HCC cells Figitumumab IC
30 (mg/mL)
SNU5 .10 Huh7 .10
SNU16 .10 HepG2 0.047 6 0.096
SNU216 .10 SNU354 .10
SNU484 .10 SNU368 0.062 6 0.02
SNU601 4.313 6 0.327 SNU423 .10
SNU620 .10 SNU449 .10
SNU638 .10 SNU739 .10
SNU668 .10 SNU886 .10
SNU719 0.063 6 0.098
NOTE: The IC30 values of figitumumab were determined by MTT assays, The IC30 value is the drug concentration required for 30% cell proliferation inhibition.
GC=gastric cancer; HCC=hepatocellular carcinoma.
doi:10.1371/journal.pone.0033322.t001
Figure 1. Anti-proliferative effect of figitumumab. A) Analysis of the anti-proliferative effect of figitumumab on gastric and hepatocellular
carcinoma cells. Two groups of cancer cells, including nine gastric cancer cell lines and eight hepatocellular carcinoma cell lines, were treated with
increasing concentrations of figitumumab (0, 0.1, 1, and 10 mg/mL) for 120 h to inhibit the growth of the control cells by 30%. Cell proliferation was
assessed by an MTT assay. Six replicate wells were used for each analysis, and at least three independent experiments were conducted. Data from
replicate wells are presented as the mean of the remaining cells. Bars=6SE. B) Effect of figitumumab on the IGF1R signaling pathway.
Immunoblotting analysis was performed to observe the dose-response effect of figitumumab (0.1–10 mg/mL) on IGF1R signaling. SNU638, SNU719,
SNU354, HepG2, and SNU368 cells were exposed to increasing concentrations of figitumumab for 72 h. The levels of proteins associated with the
IGF1R pathway and their activated forms were analyzed. Differences relative to the control are shown. In each panel, representative blots from three
independent experiments are shown. C) Effect of figitumumab on the cell cycle distribution. Figitumumab-sensitive cells (SNU719, HepG2, and
SNU368) were treated with increasing concentrations of the drug [0 mg/mL (black solid bar), 0.1 mg/mL (gray solid bar), 1 mg/mL (white bar), and
10 mg/mL (dark gray hatched bar)] for 48 h and then stained with propidium iodide, and analyzed by flow cytometry. The percentage of cells in the
G0/G1, S, and G2/M phases are shown. Columns represent the mean of three independent experiments; Bars=6SE. *P-values ,0.05, **P-values
,0.01. D) Effect of figitumumab on tumor growth in mice bearing HepG2 xenografts. HepG2 cells (1610
7) were injected into the right flank of nude
mice (n=5). Treatment with figitumumab (125 mg/mL [6.3 mg/kg body weight], once per week for 3 wk) was initiated once the tumor volume had
reached 200 mm
3. No significant body weight loss was observed during the course of the study. The tumors were measured with calipers at regular
intervals. Solid circles=treatment with vehicle control alone (control), Open triangles=treatment with figitumumab. Differences between the two
groups (tumor sizes of the control mice and those of mice treated with figitumumab) were compared from day 17 until the end of the treatment
period (day 21) using a two-sided Student’s t test. *P-values ,0.05; **P-values ,0.01 versus control.
doi:10.1371/journal.pone.0033322.g001
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PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e33322Figure 2. Analysis of IGF1R, IR, and IGF1R/IR HR levels in cancer cells sensitive to anti-IGF1R antibody. A) Immunoblot analysis of total
IGF1Rb and IRb protein levels. Two types of gastric and hepatocellular carcinoma cells were harvested 24 h after plating and immunoblotting with
anti-IGF1Rb antibody, anti-IRb antibody, and anti-a tubulin antibody was performed. For both types of cells, representative blots from three
independent experiments are shown. B) Analysis of the presence of IGF1R/IR heterodimeric receptor (HRs) using immunoprecipitation. Total cellular
proteins (1 mg) from cells were used for immunoprecipitation with anti-IGF1R antibody, separated by SDS-PAGE at constant voltage (80 V), and
Western blotted with an anti-IRb antibody. The blot was then stripped and reprobed with anti-IGF1Rb antibody C) Quantitative analysis of IGF1R
homodimer, IR homodimer, and IGF1R/IR heterodimer levels using an ELISA. Lysis buffer (100 mL) containing equal amount of proteins (50 mg/well)
from 11 cancer cell lines including MCF7 cells (positive control) were plated on anti-IGF1R antibody-coated wells and detected with an anti-IR
detection antibody. Anti-IR antibody-coated wells, IR protein standards, and the anti-IR detection antibody were used as standards in the
heterodimeric receptor ELISA. Absorbance was measured at 450 nm. Values are expressed as the mean6SEM nanograms of receptor protein per
50 mg total protein. Cell lines are listed according to their sensitivity to figitumumab. Bars=6SE. D) Effect of figitumumab on IGF1- mediated IGF1R/IR
HRs. Cells were serum-starved for 24 h and then treated with figitumumab, IGF1, or left untreated. SNU719 cells were incubated with figitumumab
(10 mg/mL) for 1 h at 37uC followed by stimulation with IGF1 (100 ng/mL) for 30 min. Immunoprecipitation was performed with an anti-IGF1R
antibody and Western blotted. Input=total cell lysate without IP.
doi:10.1371/journal.pone.0033322.g002
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whether IGF1R/IR HR formation due to increased IR protein
levels could enhance drug sensitivity, we performed MTT assays.
The result showed that IR-transfected cells were more sensitive to
the increased anti-proliferative effect of figitumumab (Figure 3B).
These results indicated that elevated levels of IR and IGF1R
enabled cancer cells to form IGF1R/IR HRs and increased their
anti-proliferative response to figitumumab.
N-linked glycosylation of IGF1R and IR in sensitive cells
Aside from the association between HRs and drug sensitivity,
we also found that N-linked glycosylation (NLG) is an additional
important factor that influences the response to figitumumab.
Blotting for the anti-IGF1Rb subunit revealed two isoforms
around 95 and 105 kDa in most cells; however, sensitive cells
showed a weak 105 kDa band and a stronger bands at 115 kDa
(Figure 4A). In short, IGF1Rb in figitumumab-sensitive cells
migrated more slowly on SDS-PAGE than that in resistant cells.
Interestingly, blotting for the anti-IRb subunit produced the same
band pattern as that of IGF1Rb. In order to determine whether
differences in molecular mass between sensitive and resistant cells
were due to differences in N-glycosylation, we enzymatically
deglycosylated IGF1R and IR with PNGage F, which removed all
types of N-linked glycans. Treatment with PNGage F increased
the electrophoretic mobility of both IGF1Rb and IRb in all
figitumumab-sensitive cells (Figure 4B), indicating that IGF1Rb
and IRb in the sensitive cells were mostly N-linked glycosylated.
A specific NLG site of IGF1R in figitumumab-sensitive
cells
We next determined whether the variation of NLG of the
IGF1Rb subunit could be another candidate biomarker for
figitumumab sensitivity. To identify a specific NLG site within
the IGF1Rb subunit, we used a combination of enzymatic de-
glycosylation and mass spectrometry (MS) analysis. After evaluat-
ing the samples from both sensitive and resistant cells, we
identified site-specific glycosylation at Asn900 and Asn913 among
five putative NLG sites (Asn747, 756, 764, 900 and 913) of the
IGF1Rb subunit. Other NLG sites (Asn747, 756 and 764) were
difficult to identify due to the presence of multiple NLG sites and
the lack of proteolytic cleavage sites within the peptide sequence
region (Figure 5A). Therefore, we focused on the Asn900 and
Asn913 residues to evaluate site-specific NLG differences between
the figitumumab-sensitive and resistant cells. A complete peptide
fragmentation patterns of the tryptic peptide (
897NPGNYTAR
904)
contained formerly N-glycosylated peptide at the Asn900 (an
addition of +1 Da, N+1) was observed from both sensitive and
resistance cells, which encompassed the Asn residue of the
glycosylation site at Asn900 (Figure S7). These results demon-
strated that Asn900 was glycosylated in both drug-sensitive and
resistant cells. However, peptides with NLG at Asn913 were
identified only in the sensitive, but not resistant cells, suggesting
that this specific NLG site was not glycosylated in the resistant
cells.
To further verify the NLG consensus site (N913) and its
functional importance, a site-directed IGF1R mutant was
constructed. Asn913 was replaced with a glutamine residue to
yield an N913Q (Asn913 ln) mutant. To assess the functional
consequences of this mutation, wild-type IGF1R and the mutant
construct were transiently expressed in Huh7 cells. As shown in
Figure 5B, the expression levels of wild-type and mutant IGF1R in
the transfected cells were increased remarkably compared to cells
transfected with the empty pcDNA3.1(-) vector. However, the
N913Q mutation appeared as a 105 kDa band that migrated
faster than the wild-type protein which produced a similar
migration pattern of the protein on SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) in SNU719 cells. These observations
confirmed that the ,115 kDa band in sensitive cells corresponded
to IGF1R that was NLG at N913.
Interestingly, it seems that removal of N-linked sugars from
N913 of the IGF1R had no apparent effect on the formations of
IGF1R/IR HRs. Rather, this mutation only affected on the NLG
state of the receptor because HR levels were remarkably increased
in the mutant IGF1R-transfected cells and the mutant receptor
showed an increased migration rate on SDS-PAGE (Figure 5C).
This result suggested that removal of the N-linked sugar from the
N913 site altered the SDS-PAGE banding profile of IGF1Rb but
had no effect on the heterodimerization of IGF1R and IR.
NLG regulates IGF1R localization to the plasma
membrane and determines sensitivity to figitimumab
We next performed an immunofluorescence assay to determine
whether mutation of the N913 consensus site prevented cell
surface expression of IGF1R. Cells expressing wild-type IGF1R
had an abundance of plasma membrane-bound IGF1R whereas
the mutant form was primarily retained inside the cells with
relatively little or no plasma membrane localization (Figure 5D).
To assess the functionality of NLG-deficient-IGF1Rs compared to
the wild-type form, we performed MTT assays. The results
showed that the anti-proliferative effect of figitumumab was
increased by overexpressing wild-type IGF1R, whereas cells
transfected with the mutant IGF1R did not display any changes
in drug sensitivity (Figure 5E). These results suggested that a lack
of N-linked sugars at N913 in the IGF1R caused predominantly
cytoplasmic localization of the receptor whereas wild-type IGF1R
appeared to localize to the plasma membrane with increased
sensitivity to figitumumab. Therefore, NLG at N913 appears to be
Table 2. Summary of measured IGF1R homodimer, IR
homodimer, and IGF1R/IR heterodimeric receptor values.
Cancer cell lines Content of receptor (ng/50 mg protein)
IGF-1R IR HRs
GC
SNU638 0.574 6 .01 0.725 6 .01 0.425 6 .01
SNU601 1.87 6 .03 1.923 6 .08 0.76 6 .01
SNU668 6.226 6 .05 0.178 6 .01 0.41 6 .003
SNU719 1.464 6 .04 2.293 6 .002 0.902 6 .01
HCC
SNU354 0.499 6 .002 1.174 6 .039 0.446 6 .007
SNU368 3.188 6 .086 0.869 6 .008 0.953 6 .012
SNU449 6.143 6 .046 0.289 6 .012 0.482 6 .003
SNU739 10.567 6 .226 0.079 6 .005 0.397 6 .01
SNU886 2.766 6 .017 0.326 6 .024 0.47 6 .006
HepG2 5.633 6 .012 2.06 6 .102 0.985 6 .013
BC
MCF7 14.903 6 .1 0.261 6 .01 0.535 6 .01
NOTE: Values are mean 6 SEM nanograms of receptor protein/50 mg total
protein.
Abbreviation: IGF1R=Insulin like growth factor 1 receptor; IR=Insulin receptor;
HR=Heterodimeric receptor; GC=Gastric cancer; HCC=Hepatocellular
carcinoma; BC=Breast cancer.
doi:10.1371/journal.pone.0033322.t002
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increased response to anti-IGF1R antibody in cancer cells.
Discussion
Figitumumab (CP-751,871) has been actively tested in patients
with multiple myeloma, but the identification of biomarkers and
mechanisms is needed to predict treatment responses and thus
help with patient selection to maximize clinical benefits. Data from
the present study suggest that the level of IGF1R/IR HRs can be a
possible diagnostic biomarker for predicting sensitivity to anti-
IGF1R antibody, particularly in GC and HCC cells. Previous
studies have reported that the level of IGF1R itself may have
predictive value in breast, lung, and colorectal cancers [31,34]. In
our study, however, neither expression of IGF1R alone nor levels
of other IGF1R associated molecules, including IRS1, could be
used to sufficiently predict figitumumab sensitivity (data not
shown). Instead, we found that an important factor for the
response to figitumumab seemed to be high expression levels of IR
because only drug-sensitive cells showed high levels of IR as well as
IGF1R (Figure 2A). Considering that several previous studies
showed that overexpression of both IGF1R and IR may lead to an
increased formation of IGF1R/IR HRs and expand the pool of
IGF1 binding sites in various human malignancies [2,3,27,35], we
therefore focused on the concept that the level of IGF1R/IR HRs
may be an important molecular biomarker for predicting
figitumumab sensitivity. Consistent with these earlier reports, we
observed that higher IR expression in the cells produced a greater
number of endogenous HRs. Furthermore, figitumumab effec-
tively disrupted IGF1-mediated IGF1R/IR HR formation,
predominantly in cells overexpressing the HR. We also examined
changes of IGF1R/IR HR levels in a mouse HepG2 xenograft
model and determined that figitumumab reduced the expression
of IGF1R/IR HRs (Figure S3B). This observation indicated that
anti-IGF1R antibodies may preferentially act against cancer cells
overexpressing IGF1R/IR HRs.
Although the physiological role of IGF1R/IR HRs is still
unclear, a number of previous studies have indicated that they play
major roles that may be more important than that of IGF1R [33].
This is because HRs, especially those containing IR-A hemi-
dimers, have a broad binding specificity. IR-A expression up-
Figure 3. Effect of selective IR overexpression on HR levels and the anti-proliferative effect of figitumumab in IR-transfected cells.
A) Effect of IR transfection on IGF1R/IR HR levels in IR-negative cell lines. Cells were transfected with the pcDNA3.1(-) expression vector containing
wild-type IR cDNA. An equal amount of lysates from cells transfected with either the empty vector or pcDNA3.1(-) containing IR cDNA was subjected
to immunoprecipitation with an anti-IGF1R antibody followed by Western blot analyses of IRb and IGF1Rb. B) Effect of IR-transfection on figitumumab
sensitivity. Transfected cells were plated onto 96-well plates, treated with figitumumab for 5 d, and subjected to MTT assays. Solid triangle symbol
with dashed lines=empty vector (pcDNA3.1-), Solid circle symbols with lines=pcDNA3.1(-) IR. Bar=6SE. Mean values were derived from six
replicates. Experiments were repeated in triplicate.
doi:10.1371/journal.pone.0033322.g003
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heterodimers for IGFs and allowing insulin to activate the IGF1R
in heterodimers [29]. In other words, overexpression of IR serves
as a major mechanism of IGF1R signaling in cancer cells [36] by
enabling the formation of more heterodimers which are available
for binding ligands including IGF1, IGF2, and insulin. As a result,
several studies have revealed the increased effectiveness of
targeting heterodimeric receptors or simultaneously targeting both
the IGF1R and IR as novel anti-cancer therapies compared to
targeting IGF1Rs alone [30,37,38]. Moreover, our data extended
previous studies indicating that monoclonal antibodies targeting
both IGF1R and HRs markedly inhibit the growth of thyroid and
breast cancer cells with high HR:IGF1R ratios [27]. Another
study also showed that targeting IGF1R/IR HRs resulted in a
more potent anti-tumoral response compared to antibodies
targeting only IGF1Rs [30].
Aside from the association between HRs and figitumumab
sensitivity, our results showed that NLG of the IGF1R and IR was
another important indicator of drug sensitivity. We found that
IGF1Rb and IRb showed an upward shifting on SDS-PAGE in all
three figitumumab-sensitive cells compared to resistant cells
(Figure 4A); the migration rate of these bands also increased
following treatment with PNGage F (Figure 4B). These findings
indicate that there was a variation in the addition of N-linked
oligosaccharide to IGF1Rs in cancer cells. To verify this
hypothesis, we identified a glycosylation site (N913) occupied by
an N-linked sugar in only figitumumab-sensitive cells using a mass
spectrometry approach. We also confirmed that NLG was
required for efficient surface expression of IGF1R and sensitivity
to figitumumab since removal of N-linked sugars via mutagenesis
(N913Q) resulted in a predominantly cytoplasmic localization of
the IGF1R and markedly reduced receptor translocation to the
plasma membrane. These findings suggest that N913 in the
IGF1R may be a specific glycosylation site needed for receptor
translocation to the cell surface. Without post-translational NLG
modification of the IGF1R at this site, IGF1R/IR HRs apparently
fail to localize to the plasma membrane, thus preventing receptor-
ligand binding and decreasing the efficacy of anti-IGF1R
antibody-based cancer therapies.
Recently, a recent phase III trial of figitumumab administered
in combination with carboplatin and paclitaxel failed to
demonstrate survival benefit in advanced NSCLC patients. The
study showed that the use of figitumumab with paclitaxel/
carboplatin would be unlikely to improve overall survival
compared to paclitaxel/carboplatin alone, mainly due to toxicity
occurring in patients who randomly received figitumumab [15].
This study highlights the importance of selecting appropriate
patients for clinical trials evaluating the anti-IGF1R antibody.
Thus, additional studies identifying biomarkers for predicting the
response to anti-IGF1R antibody are necessary. In this respect,
our study may help identify a subset of cancer patients who would
preferentially benefit from figitumumab therapy and provide
important information for designing and conducting future clinical
trials of figitumumab.
Figure 4. Analysis of NLG of IGF1Rb and IRb in figitumumab-sensitive cell lines. A) Immunoblot analysis of different IGF1Rb migration
pattern on SDS-PAGE. Electrophoretic mobility patterns of IGF1Rb were analyzed in parallel by Western bloting. Experiments were repeated at least
three times with similar results. B) Analysis of N-glycosylated IRb and IGF1Rb in sensitive cell lines by enzymic deglycosylation with PNGage F. All
samples were incubated at 37uC for 12 h with PNGage F. IGF1Rb and IRb proteins were analyzed in parallel by Western blotting. The blots shown are
representatives of three independent experiments.
doi:10.1371/journal.pone.0033322.g004
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PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e33322Although figitumumab failed to improve overall survival in the
phase III trial, a subset analysis of this study offered clues about a
potential predictive biomarker for predicting the response to
figitumumab. In this analysis, patients with circulating levels of
IGF1 of greater than 1 ng/mL experienced improved treatment
outcomes including increased overall survival after receiving
figitumumab with chemotherapy. More recently, the study by
Gualberto et al. showed that higher pre-treatment levels of fIGF1
(.1 ng/mL) were predictive of the clinical benefit derived from
the use of figitumumab with chemotherapy in NSCLC patients
[39]. This group concluded that tumors which developed in a
patient with high IGF bioactivity were more likely to become
dependent on IGF1R signaling, and therefore may be more
sensitive to figitumumab. This is not in contradiction with our data
from experiments designed to identify potential predictive
biomarkers of figitumumab sensitivity. Based on our finding, we
suggest that heterodimerization of NLG IGF1R with IR in cancer
cells may be a potential biomarker for predicting figitumumab
sensitivity because cancer cells expressing more functional
membrane-bound IGF1R/IR HRs that bind IGF1 ligands were
more sensitive to treatment with anti-IGF1R antibody. Moreover,
elevated levels of circulating IGF1 ligands might be associated with
increased formation of IGF1R/IR HRs. Since increased levels of
IGF1 ligand can mediate the formation of more IGF1R/IR HRs,
preventing IGF bioactivity by blocking the interaction of IGFs
with IGF1R/IR heterodimeric receptors, which play major roles
in mediating the IGF/IGF1R signaling axis, might contribute to
the anti-tumor activity of figitumumab in cancer cells dependent
on IGF1R signaling. Therefore, we believe that functional
membrane-bound IGF1R/IR HRs could be as important as
fIGF1 levels for predicting sensitivity to anti-IGF1R antibody
therapy.
In conclusion, data from the present study suggested that N-
linked glycosylated IGF1R/IR HR levels can be a biomarker for
predicting the response to figitumumab. To validate our results,
similar experiments should be performed in preclinical and clinical
settings. For example, we might be able to evaluate the levels of
NLG IGF1Rs, IRs, and HRs in tissue samples from GC or HCC
patients who respond favorably to figitumumab therapy using
immunohistochemistry-based assays. This could confirm whether
the level of functional membrane-bound IGF1R/IR HRs is an
important predictor of sensitivity and responsiveness to targeted
anti-IGF1R antibody-based therapy.
Materials and Methods
Cell Culture and Reagents. uman gastric cancer cells
(SNU5, 16, 216, 484, 601, 620, 638, 668 and 719) and
hepatocellular carcinoma cells (SNU354, 368, 423, 449, 739,
and 886) were obtained from the Korea Cell Line Bank (Seoul,
South Korea) [40], and HepG2 and Huh7 were purchased from
the American Type Culture Collection (Manassas, VA). All cells
were grown at 37uC with 5% CO2 in RPMI-1640 containing 10%
fetal bovine serum (WelGENE Inc., Seoul. Korea). Figitumumab
(CP-751,871) was provided by Pfizer Global R&D (CT, USA). A
stock solutions (5 mg/mL) were stored at 4uC and diluted in fresh
media before each experiment. Insulin growth factor 1 (IGF1) was
purchased from Sigma-Aldrich (St. Louis, MO).
Growth Inhibition Assay. Tetrazolium dye (3-(4,5-
dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide [MTT];
Sigma-Aldrich, St.Louis, MO) assays were used to evaluate the
growth inhibitory effect of figitumumab. Cells were seeded in
RPMI-1640 containing 10% fetal bovine serum in 96-well plates at
a density of 3610
3 per well. After an over-night incubation, the cells
were grown for 5 d in the presence of figitumumab (0, 0.1,1.0, and
10 mg/mL) at 37uC. After drug treatment, MTT solution was
added to each well and the cells were incubated for 4 h at 37uC
before the media were removed. Dimethyl sulfoxide (DMSO;
150 mL) was then added to each well, and the solution was shaken
for 30 min at room temperature. Absorbance of each well was
measured at 540 nm, using a microplate reader (Versa-Max,
Molecular Devices, Sunnyvale, CA). Graphs were generated by
nonlinear regression analysis of the data points to a four parameters
logistic curve using SigmaPlot software (Statistical Package for the
Social Sciences, Inc., Chicago, IL), and the IC30 value was
calculated. Six replicate wells were included in each analysis, and at
least three independent experiments were conducted.
Cell Cycle Analysis. Cells were plated in 60-mm dishes and
grown to 50% confluence. After 24 h, the medium was exchanged
with the test medium containing figitumumab (0, 0.1,1.0, and
10 mg/mL). After 48 h, the treated cells were harvested and fixed
overnight with cold 70% ethanol at –20uC. After washing with
PBS, the samples were incubated with 10 mg/mL RNase A
(Sigma-Aldrich) and stained with 20 mg/mL propidium iodide
(Sigma-Aldrich). Flow cytometric analysis (FACSCalibur flow
cytometer; Becton Dickinson Biosciences, San Jose, CA) was
performed; at least three independent experiments were
conducted.
Figure 5. Identification of a specific N-linked glycosylation site (N913) of IGF1R in sensitive cell lines and its functional importance
in the response to figitumumab. A) Identification of the NLG site occupancy of IGF1Rb subunits. IGF1Rb subunits containing N-linked
glycosylation sites (Asn747, Asn756, Asn764, Asn900, and Asn913) were isolated from both drug sensitive (SNU719, HepG2 and SNU368) and
resistance (SNU638 and SNU354) cells and identified by tandem MS by an increase of 1.0 Da from the corresponding mass of Asn as a result of
conversion from N-linked glycosylated Asn to Asp. All the NLG at Asn900 in both sensitive and resistance cells were determined to be occupied with
N-glycosylation (filled rectangle). NLG at Asn913 of the sensitive cell lines (HepG2, SNU719, and SNU368) were determined to be occupied with N-
glycosylation (filled rectangle), whereas N-glycosites at Asn913 of the resistance cell lines (SNU638 and SNU354) were found to be unoccupied with
N-glycosylation. (open rectangle). B) Effect of the N913Q site mutation on electrophoretic mobility patterns of IGF1Rb. Huh7 cells (an IGF1R-negative
cell line) were transfected with the empty pcDNA3.1(-) expression vector(Control), pcDNA3.1(-) containing wild-type IGF1R cDNA (IGF1R WT), or
pcDNA3.1(-) with IGF1R mutation type cDNA (IGF1R N913Q). An equal amount of the cell lysate from the transfected cells was then subjected to
Western blot analysis for IGF1Rb. C) Effect of N913Q site mutation on the formation of IGF1R/IR heterodimeric receptors. An equal amount of the cell
lysate from transfected cells was then subjected to immunoprecipitation (IP) with anti-IGF1R antibody followed by Western blot analysis for IRb and
IGF1Rb. Input=total cell lysate without IP. D) Effect of N913Q site mutation on IGF1R localization. An immunofluoresence assay was conducted to
observe the localization of IGF1R. IGF1R reactivity was visualized by confocal laser scanning microscopy (Scale bar: 30 mm). Representative images are
shown. Green: IGF1R, Blue: nuclei. E) Effect of N913Q site mutation on figitumumab sensitivity. Huh7 cells transfected with empty pcDNA3.1(-) vector,
vector containing wild-type IGF1R cDNA, or vector containing IGF1R (N913Q) mutation type cDNA were plated in 96-well plates and treated with
increasing concentrations of figitumumab for 120 h (left). Cell viability percentages with 1 mg/mL figitumumab (right). Six replicate wells were
included in each analysis, and at least three independent experiments were conducted. Data from replicate wells are presented as the mean of
remaining cells. * P-values ,0.05; ** P-values ,0.01.
doi:10.1371/journal.pone.0033322.g005
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that had reached ,70% to ,80% confluence were used for
protein analysis. The cells were washed with ice-cold phosphate-
buffered saline (PBS) and lysed in radioimmunoprecipitation assay
(RIPA) buffer (120 mM NaCl, 0.5% NP-40, 50 mM NaF,
0.2 mM PMSF, 0.1 mM pepstatin A, 0.2 mM leupeptin, 10 mg/
mL aprotinin, and 1 mM benzamidine). Protein concentrations
were quantified with a Bicinchoninic Acid Protein Assay Reagent
(Pierce, Rockford, IL), according to manufacturer’s instructions.
Samples containing equal amounts of total protein were resolved
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE, 7%–12%) and transferred to nitrocellulose
membranes (Whatman Protran, Dassel, Germany). The
membranes were incubated in blocking solution containing 1%
nonfat dry milk and 1% bovine serum albumin for 1 h at room
temperature and probed overnight at 4uC with antibodies against
p-IGF1Rb (pY-1131/1146, dilution 1:500), p-IRb (pY-1361,
dilution 1:500), p-IRS(pS302, dilution 1:500), p-STAT3 (pY-705,
dilution 1:1000), p-AKT (pS-473, dilution 1:1000), p-ERK (pThr-
202/Tyr-204, dilution 1:1000), IGF1Rb,I R b, STAT3, AKT, and
ERK, which were purchased from Cell Signaling Technology
(Beverley, MA). Anti-IRS antibody was obtained from BD (San
Jose, CA). Anti-a Tubulin was purchased from Sigma-Aldrich (St.
Louis, MO). The membranes were then incubated for 1 h at room
temperature with mouse and rabbit horseradish peroxidase-
conjugated secondary antibodies (Pierce, Rockford, IL) diluted at
1:3000 in T-TBS/1%BSA/1%dry skin milk.
Immunoprecipitation. Cells grown in 100 mm dishes were
washed twice with ice-cold PBS and scraped into ice-cold lysis
buffer (50 mM Tris-HCl [pH 7.4]), 120 mM NaCl, 0.5% NP-40,
50 mM NaF, 0.2 mM PMSF, 0.1 mM pepstatin A, 0.2 mM
leupeptin, 10 mg/mL aprotinin, and 1 mM benzamidine). Lysates
were centrifuged at 150006g for 30 min at 4uC, The supernatants
were removed and assayed for protein concentration. Lysis buffer
(600 mL) containing equal amount of proteins were pre-cleared
with protein A/G agarose beads (Upstate Biotechnology, Lake
Placid, NY) and incubated overnight with anti-IGF1R antibody
obtained from Santa Cruz Biotechnology (1:100, Santa Cruz, CA)
at 4uC with gentle rotation. Samples were then incubated with
50 mL protein A/G agarose beads (Upstate Biotechnology) for 2 h.
The beads were washed four times with lysis buffer, collected by
centrifugation, resuspended in 26protein sample buffer, and
boiled for 7 min at 100uC. Immunoprecipitated and total (input)
protein samples were then resolved in SDS-polyacrylamide gel
electrophoresis, and Western blotted with an anti-IRb antibody
and an anti-IGF1Rb antibody.
siRNA for IGF1R Knockdown. Custom siRNA specific for
IGF1R (target sequence: AACAATGAG TACAACTACCGC,
sense strand: CAAUGAGUACAACUACCGCTT, antisense
strand: GCGGUAGUUGUACUCAUUGTT), and negative
control siRNA were obtained from Qiagen (Valencia, CA) and
used to treat each cell line for 48h. The transfections were
performed with LipofectAMINE
TM 2000 (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions. siRNA against
IGF1R and negative control siRNA were used at a concentration
of 60 nM.
ELISA. Star IGF1R and IR ELISA kits were purchased from
Upstate Biotechnology. Proteins from all samples (50 mg/well) and
quantification of IR and IGF1R were performed, according to the
manufacturer’s protocol. All samples and standard were analyzed
in duplicate. To quantify HRs, reagents from both the IR and
IGF1R ELISA kits were used in combination. Anti-IR antibody-
coated wells, IR protein standards, and the anti-IR detection
antibody were used as standards for detecting HRs in the ELISAs.
Absorbance was measured at 450 nm, using a microplate reader
(Versa-Max, Molecular Devices).
Enzymatic Deglycosylation of the IGF1Rb and IRb
Subunits. Enzymatic deglycosylation was performed with
PNGase F [cat. no. R7884] purchased from Sigma-Aldrich (St.
Louis, MO). Cultured cells were washed with ice-cold PBS and
lysed in RIPA buffer. The lysates were then treated with 2 mLo f
500 units/mL PNGase F and incubated at 37uC for 12 h. The
reactions were stopped by heating to 100uC for 5 min. Samples
containing equal amounts of total protein were then resolved on
SDS-polyacrylamide denaturing gels (7%–12%) at a consistent
voltage (80 V).
SDS-PAGE. Immunoprecipitated samples with figitumumab
were loaded onto 4–12% SDS-PAGE gels, and run with MOPS/
SDS running buffer (Invitrogen, Carlsbad, CA). The gel regions of
interest were excised, in-gel digested, and extracted, as described
previously [41]. Briefly, protein bands were excised and the
cysteine residues were reduced with 15 mM TCEP (Sigma-
Aldrich, St. Louis, MO, USA) and alkylated with iodoacetamide
(Sigma-Aldrich). After dehydration with CAN, the proteins were
digested with 30L of 12.0 ng/L modified porcine trypsin
(Promega, Madison, Wi, USA) in 25 mM NH4HCO3, overnight
at 37uC. Peptides were extracted with 60% v/v ACN in 1% formic
acid, dried under vacuum. The dried peptide mixture was re-
suspended in 50 mM NH4HCO3 and incubated with PNGase F
(New England BioLabs, Ipswich, MA, USA) at 37uC for overnight.
The deglycosylated peptide mixture was purified using a C18-
desalting cartridge following the general protocol.
Mass Spectrometry Analysis. The dried peptide samples
were dissolved in 20 mL 0.1% formic acid in H2O. The extracted
peptidesamplesfromthein-geldigestionweresubjectedtoLC-MS/
MS analysis on an LTQ-velos (ThermoFinnigan, San Jose, CA),
coupled on-line with a nano-HPLC system (Proxyon, Copenhagen,
Denmark), and equipped with a reversed-phase microcapillary
electrospray ionization system [42]. 3 mL of the peptide mixtures
wereloadedontotheHPLCconnectedwithanin-house,packedC18
column (10 cm length, 75 mm inner diameter). The peptides were
sequentially eluted from the HPLC column with a gradient of 5 to
90%ofbufferB(acetonitrile:water:formicacid,98.5:1:0.5)inBuffer
A (water:acetonitrile:formic acid, 98.5:1:0.5 [v/v/v/], at a flow rate
of,0.2 mL/min.Theelutedpeptidesweresprayeddirectlyfromthe
tip of the capillary column to the LTQ mass spectrometer for mass
spectrometry analysis. The LTQ was operated in a data-dependent
modewherethemachinemeasuredintensityofallpeptideionsinthe
massrangeof400to1400(mass-to-chargeratios).Thetopthreemost
intense ions were isolated for collision-induced dissociation.
Precursor ions were excluded after being targeted for MS/MS
fragmentationafterthreescansina30 secondperiod.Rawfileswere
converted into mzXML files and peptides were assigned using
SEQUEST [43] search against the human IPI database
(version 3.80). All searches were performed with trypsin specificity
allowing one missed cleavage. Cysteine modification with
iodoacetamide was considered as fixed, oxidation of methionine,
and 1 Dalton addition to asparagines as variable modification. The
search considered a precursor ion mass tolerance of 1.5 Da, a
fragment ion ass tolerance of 0.5 Da. Peptide assignments were
validated using PeptideProphet [44], and the protein inference
performed using ProteinProphet [45]. The list of protein
identification s was filtered using a 0.9 probability threshold, which
corresponds to less than 1%estimated false discovery rate.
Plasmid Constructs and Transient Transfection. Full-
length IR cDNA (accession number BC117172) from pCR-XL
TOPO (Thermo Scientific, Huntsville, AL) was isolated by double
digestion with HindIII/XbaI (New England Biolab, Ipswich, MA)
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(Invitrogen). Full-length IGF1R cDNA (accession number
BC113610) from pCR-XL TOPO was isolated by digesting with
EcoRI (New England Biolab) and subcloned into pcDNA3.1-. To
obtain mutant IGF1R cDNA, a point mutation converting an
asparagine to glutamine (N913Q) was introduced into wild-type
IGF1R cDNA using a QuickChange Site-Directed Mutagenesis
kit (Stratagene. La Jolla, CA) according to the manufacturer’s
protocol with the following primers: CACATCTCTCTCTGG-
GCAGGGGTCGACAGATC (forward) and GATCTGTCC-
ACGACCCCTGCCCAGAGAGAGATGTG (reverse). IGF1R
cDNA constructs were cloned into pcDNA3.1(-) plasmids
resulting in wild type-IGF1R and mutant type-IGF1R (IGF1R
WT and IGF1R N913Q). The mutant construct sequence was
confirmed by site-directed sequencing using the following primers:
TGAGGATCAGCGAGAATGTG (forward) and CAGAGGC-
ATACAGCACTCCA (reverse). pcDNA3.1(-) vectors encoding
the sequence for IR, wild type IGF1R, or mutant IGF1R(N913Q:
AATCAG), were then used to transiently transfect into cancer
cells. For transfections, 8 mL of LipofectAMINE
TM 2000
(Invitrogen) with 100 mL of serum- and antibiotic-free RPMI-
1640 was added to 4 mg of pcDNA3.1(-) constructs harboring IR,
wild type IGF1R, or mutant IGF1R (N913Q). After 20 min, the
LipofectAMINE/cDNA solution was diluted with 4.8 ml of
serum-free RPMI-1640 then incubated at 37uC in 5%CO2 for
6 h. The transfection medium was then replaced with complete
culture media consisting of RPMI-1640, containing10% fetal
bovine serum.
Immunofluorescence. In order to detect IGF1R localization,
Huh7 cells grown on glass cover slips for 1 d were transfected with
pcDNA3.1(-) vectors encoding the sequence for wild type IGF1R or
mutant IGF1R (N913Q) for 48 h. After rinsing with PBS at room
temperature, cells were fixed for 30 min with 3.7% para-
formadehyde. After permeabilization with 0.1% Triton X-100 for
4–5 min, blocking was performed in 5% normal serum in PBS for
1 h at 37uC. The cells were then incubated overnight with anti-
IGF1R antibody (1:100, Cell Signaling Technology) at 4uC. After
rinsing with PBS, the slides were incubated with conjugated goat
anti-rabbit antibody (1:1000, Invitrogen) for 1 h at room
temperature. After washing with PBS, the cover slips were
mounted onto glass slides in mounting reagent (DAKO, Glostrup,
Denmark). All experiments were repeated three times. Digital
images were acquired with a laser-scanning confocal microscope
(Carl Zeiss, Jena, Germany) using appropriate lasers.
HepG2 Xenograft Model. All animal experiments were
carried out in the animal facility of the Seoul National University in
accordance with institutional guidelines. To determine the in vivo
activity of figitumumab, 4-wk-old female BALB/c (nu+/nu+)
athymic nude mice were purchased from Central Lab Animal Inc.
(Seoul, South Korea) and were permitted to acclimatize to specific
pathogen-freeconditionsfor1 wkbeforebeinginjectedwithHepG2
cancer cells in 100 mL of PBS (1610
7 cells per 100 mL PBS).
Figitumumab was diluted in PBS. The vehicle control group was
givenPBSalone.Whenthetumorsreachedavolumeof200 mm
3,the
mice were were randomly divided into groups (n=five mice per
group)thatreceivedeithervehicle(PBS)orfigitumumab(125 mg/mL
[6.3 mg/kgbodyweight]permouse:onceperwk)intraperitoneally.
The tumor volume was determined by measuring the tumor mass
every other day using calipers, and calculated according to the
followingformula:[(width)
26(height)
2]/2.Thegeneralhealthofthe
mice and body weight were monitored at the time of tumor
measurement. After the final treatment, all mice were euthanized
according to institutionalguidelines.
Statistical Analysis. A two-sided Student t-test was used as
appropriate to compare tumor sizes in the xenograft-bearing mice.
An unpaired two-tailed t-test was used to determine significant
changes in cell viability and G1 arrest. Means 6 SD are shown.
All P-values ,0.05 were considered statistically significant.
Supporting Information
Figure S1 Anti-IGF1R antibody (figitumumab) induced
receptor internalization and degradation. Time-dependent
IGF1Rb and IRb protein degradation following figitumumab
treatment. All cells (SNU719, SNU668, SNU638, SNU354,
SNU368, SNU739, and HepG2) were treated with figitumumab
(10 mg/mL) in complete medium at 37uC for the designated time
periods. Cells were harvested at each time (1 h, 3 h, 6 h, 12 h,
24 h, 72 h) and lysed. The levels of IGF1R b and IR b proteins
were analyzed in parallel by Western blotting. Representative blots
from three independent experiments are shown.
(TIF)
Figure S2 A) Effect of small-interfering RNA (siRNA) on
IGF1R and IGF1R downstream molecules. Custom iRNA
specific for IGF1R (target sequence: AACAATGAG TACAAC-
TACCGC, sense strand: CAAUGAGUACAACUACCGCTT,
antisense strand: GCGGUA GUUGUACUCAUUGTT), and
negative control siRNA were used at concentrations of 60 nM.
SNU638, SNU719, SNU354, HepG2, and SNU368 cells were
transfected with siRNA specific for IGF1R and negative control
siRNA(60 nM).After48 h,celllysateswereWestern-blottedwiththe
indicated antibodies. Representative blots from three independent
experimentsareshown.B)Effectofsmall-interferingRNAs(siRNA)
againstIGF1Rontheanti-proliferativeeffectinsensitivecells.siRNA
specificforIGF1RandnegativecontrolsiRNA(60 nM)wereusedto
transfect SNU638, SNU719, SNU354, SNU368, and HepG2 cells.
After 48 h, cell were plated in 96-well plates and subjected to MTT
assays. Mean values were derived from six replicates. Differences
betweenthetwogroupswereconsideredtobestatisticallysignificant
(Bars=6SE.*P-values ,0.05; **P-values,0.01).
(TIF)
Figure S3 Effect of figitumumab in in vivo mouse
models. A) Effect of figitumumab on activated IGF1R and
IRS1 proteins in in vivo mouse models. After 1 d of figitumumab
treatment initiation, the animals were sacrificed and the tumors
were removed. The tumors were then homogenized by grinding
the tumors in ice-cold lysis buffer to observe the changes in P-
IGF1Rb, IGF1Rb, P-IRS1, IRS1, and a-tubulin protein expres-
sion. B) Effect of figitumumab on IGF1R/IR heterodimeric
receptor levels in tumor tissues. On day 1 after figitumumab
treatment, xenograft tumors were excised from euthanized mice
from each group and snap frozen in liquid nitrogen. Tumors were
then lysed with immunoprecipitation lysis buffer (50 mM Tris-
HCl, pH 7.4) to detect changes in IGF1R/IR heterodimeric
receptor levels. Samples were resolved in SDS-polyacrylamide
denaturing gels (7.5%) with consistent voltage (80 V).
(TIF)
Figure S4 Figitumumab recognizes IGF1R/IR hetero-
dimeric receptors. Lysates containing an equal amount of total
protein (1 mg/mL) were immunoprecipitated with 1 mLo f
figitumumab (CP-751,871: 5 mg/mL) and Western-blotted with
antibodies against IGF1Rb and IRb. Both IGF1Rb and IRb in
SNU719, SNU368, and HepG2 cells were detected at high levels
in the immunoprecipitates. The SNU601 cells, which showed
modest sensitivity to figitumumab, also contained IGF1R/IR
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experiments are shown.
(TIF)
Figure S5 Anti-proliferative effect of figitumumab on
MCF7 cells. MCF7 breast cancer cells were used as a positive
control for ELISA. The cells were treated with increasing
concentrations of figitumumab (0, 0.1, 1.0, 10 mg/mL) for
120 hours to inhibit the growth of control cells by 30%. Six
replicate wells were included in each analysis, and at least three
independent experiments were conducted. The data from replicate
wells are presented as the mean of the remaining cells. Bar=6SE.
(TIF)
Figure S6 Effect of figitumumab on insulin mediated
IGF1R/IR heterodimeric receptors. Figitumumab could not
inhibitinsulin-mediatedsignalsoraffecttheformationofIGF1R/IR
heterodimericreceptors.A)Allcellswereserum-starvedfor24 hours,
and then treated with insulin (100 nmol; 30 min) or figitumumab
(10 mg/mL; 4 hours). SNU719 cells were incubated for 4 hour at
37uC with figitumumab followed by stimulation with insulin for
30 minutes. Total cellular extracts (1 mg) were extracted using IP
buffer (pH 7.4), immunoprecipitated with anti-IR antibody, and
Western blotted with anti-IGF1R antibody. The blot was then
stripped and reprobed with anti-IRb antibody to ensure equivalent
loadingofanti-IRantibodyinallsamples.B)Effectoffigitumumabon
insulin-mediated IGF1R signaling. SNU719 cells were serum-
starved for 24 h and then treated with insulin (100 nmol; 30 min)
orfigitumumab(10 mg/mL:4 h).ThecelllysateswerethenWestern-
blottedwiththeindicatedantibodies.Representativeblotsfromthree
independent experiments are shown.
(TIF)
Figure S7 MS/MS spectra of glycosylated peptides.
IGF1Rb subunits containing N-linked glycosylation sites were
isolatedfrombothdrugsensitiveandresistancecellsbyimmunopre-
cipitation using figitumumab. The IP samples were separated by
SDS-PAGE and protein bands corresponding to the IGF1Rb
subunits were cut out and subjected to the in-gel digestion using
trypsin. The resulting tryptic peptides were deglycosylated with
PNGase F treatment. N-linked glycosylation sites were then
determined by tandem mass spectrometry analysis by an increase
of1.0 DafromthecorrespondingmassofAsnasaresultofconversion
fromN-linkedglycosylatedAsntoAsp.Majorfragmentionsreferring
tothea-,b-,andy-seriesareassigned,andtheformerlyglycosylated
aminoacidresiduesareunderlinedinthedepictedpeptidesequences.
(A) MS/MS spectrum and sequencing results of an N-glycan-
modified peptide corresponding to residues,
896LNPGNYTAR
904
areshown.TheexpectedincreaseinmassbyN-glycanmodificationis
1.0 Da at Asn 900. The major fragment ions (a-, b-, and y-series)
including N+1 (Asn900 plus 1.0 dalton) are consistent with N-
glycosylation modification at Asn 900 (underlined). (B) MS/MS
spectrum and sequencing results of an N-glycan-modified peptide
corresponding to residues,
905IQATSLSGNGSWTDPVFFYV-
QAK
927 are shown. The expected increase in mass by N-glycan
modificationis1.0DaatAsn913.Themajorfragmentions(a-,b-,and
y-series) including N+1 (Asn913 plus 1.0 dalton) are consistent with
N-glycosylation modification at Asn913 (underlined).
(TIF)
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